B7-2

B7-2 Overview

English NameCluster of differentiation 86Approved Drugs2
Drugs in Clinical Trials7Target SynonymFUN-1,CTLA-4 counter-receptor B7.2,CD28LG2,Activation B7-2 antigen,CD86,CD86 Molecule,CD86 Antigen (CD28 Antigen Ligand 2, B7-2 Antigen),BU63,B70,B-Lymphocyte Activation Antigen B7-2,T-Lymphocyte Activation Antigen CD86,B-Lymphocyte Antigen B7-2,CD86 Antigen,LAB72,B7-2,B7.2,B7-2 Antigen
Highest Development StageApproved
English NameCluster of differentiation 86
Target SynonymFUN-1,CTLA-4 counter-receptor B7.2,CD28LG2,Activation B7-2 antigen,CD86,CD86 Molecule,CD86 Antigen (CD28 Antigen Ligand 2, B7-2 Antigen),BU63,B70,B-Lymphocyte Activation Antigen B7-2,T-Lymphocyte Activation Antigen CD86,B-Lymphocyte Antigen B7-2,CD86 Antigen,LAB72,B7-2,B7.2,B7-2 Antigen
Approved Drugs2
Drugs in Clinical Trials7
Highest Development StageApproved

B7-2 Product List

  • Product Category

    Protein (8)

  • Product Status

    Launched (8)

  • Species

    Human (3)Cynomolgus / Rhesus macaque (2)Mouse (2)Rat (1)

  • Tag

    Fc Tag (3)His Tag (4)Fc Tag & Avi Tag (1)

  • Conjugate

    Unconjugated (7)Biotin-labeled (1)

B7-2 Background

Cluster of Differentiation 86 (CD86) is also known as B-lymphocyte activation antigen B7-2, is a type I membrane protein that is a member of the immunoglobulin superfamily, and is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B72 is expressed at low levels on monocytes and can be upregulated through interferon γ. CD86 is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD86 works in tandem with CD80 to prime T cells. Recent study has revealed that B7-2 promotes the generation of a mature APC repertoire and promotes APC function and survival. Furthermore, the B7 proteins are also involved in innate immune responses by activating NF-κB-signaling pathway in macrophages. CD86 thus is regarded as a promising candidate for immune therapy. CD86+ macrophages in Hodgkin lymphoma patients are an independent marker for potential nonresponse to firstline-therapy.

B7-2 Synonyms

CD86,B7-2,B70,CD28LG2,LAB72,MGC34413

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
ORCA-010ORCA-010Phase 2 ClinicalOrca Therapeutics BvProstatic Neoplasms
Details
Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech)Z-CTLsPhase 1 ClinicalHunan Zhaotai Yongren Biotech Co LtdCarcinoma, Non-Small-Cell Lung
Details
AN-8025AN-8025Phase 1 ClinicalHangzhou Adlai Nortye Biopharma Co LtdSolid tumours
Details
M-5542M5542; M-5542Phase 1 ClinicalMerck & Co Inc
Details
Abatacept biosimilar (Kashiv BioSciences)KSHB-002; KSHB002Phase 1 ClinicalKashiv BioSciences LLCArthritis, Rheumatoid; Immune System Diseases
Details
Abatacept biosimilar (Dr. Reddy's Laboratories)DRL-ABPhase 1 ClinicalDr.Reddy's Laboratories LtdArthritis, Rheumatoid
Details
Recombinant human CTLA-4-FC fusion protein(Beijing Vdjbio)VDJ002; VDJ-002Phase 1 ClinicalBeijing Vdjbio Co LtdArthritis, Rheumatoid; Lupus Erythematosus, Systemic
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
BelataceptLEA29Y; LEA-029; BMS-224818; L104EA29YIgApprovedBristol-Myers Squibb CompanyNulojixUnited StatesRejection of renal transplantationBristol-Myers Squibb Company2011-06-15Arthritis, Rheumatoid; Delayed Graft Function; Diabetes Mellitus, Type 1; Graft Rejection; Kidney Failure, Chronic; Pancreatic neuroendocrine tumors (pNET); Proteinuria; Rejection in heart transplantation; Rejection of renal transplantation; Rejection of organ transplantation
Details
AbataceptBMS-188667; ONO-4164; ONO-4164SC; BMS-188667SCApprovedBristol-Myers Squibb CompanyOrencia, 恩瑞舒United StatesArthritis, RheumatoidBristol-Myers Squibb Company2005-12-23Allergic asthma; Alopecia Areata; Anemia, Aplastic; Anemia, Diamond-Blackfan; Anemia, Sickle Cell; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Arthralgia; Arthritis; Arthritis, Juvenile; Arthritis, Psoriatic; Arthritis, Rheumatoid; Behcet Syndrome; beta-Thalassemia; Cardiovascular Diseases; Chediak-Higashi Syndrome; Colitis, Ulcerative; Common Variable Immunodeficiency; Coronavirus Disease 2019 (COVID-19); Crohn Disease; Dermatomyositis; Diabetes Mellitus, Type 1; Dyskeratosis Congenita; Eye Diseases; Fanconi Anemia; Giant Cell Arteritis; Glomerulosclerosis, Focal Segmental; Graft vs Host Disease; Granulomatosis with Polyangiitis; Granulomatous Disease, Chronic; Healthy Aging; Hematologic Diseases; Hematologic Neoplasms; Immunoglobulin G4-Related Disease; Inflammation; Kostmann Syndrome; Leukocyte-Adhesion Deficiency Syndrome; Lung Diseases, Interstitial; Lupus Erythematosus, Systemic; Lupus Nephritis; Lymphohistiocytosis, Hemophagocytic; Mucopolysaccharidosis I; Multiple Sclerosis; Multiple S
Details

Product Reviews

  • 1***22019-09-26
    0People Like
    SEC showed a high purity of the protein, which can reach to higher than 90%. Functional bioactivity is also very good. It can bind with PD-L1 in vitro. If it is used to measure affinity, the signal will be higher if pdl1 concentration is increased.
  • Overview
  • Product List
  • Marketed Drug Information
  • Product Reviews
  • Clinical Drug Information